Loading the session
Loading the session
Loading instrument
$35.13
+0.29%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:23 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
Closed at $35.03 on 4 Nov 2026: 0.1% below the 52-week high of $35.05 (4 Nov 2026) and 237.6% above the low of $10.38 (19 May 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
1 month: +43.8% (SPY −1.6%, XLV +13.5%). 3 months: +76.6% (SPY −0.4%, XLV +15.5%). 1 year: +155.7% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: XNCR, SPY and XLV · as of 4 Nov 2026
The 4 Nov 2026 gain of 14.3% was 4.8× its average daily move of 3.0% over the past year, and its largest one-day gain since 26 Oct 2026.
Daily closes, split-adjusted · as of 4 Nov 2026
12.3M shares were sold short at the 15 Oct 2026 settlement, 16.5% of the 74.4M shares outstanding; covering them would take 9.1 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
The 4 Nov 2026 close of $35.03 was 35.1% above its 50-day average ($25.92) and 103.2% above its 200-day average ($17.24). It has closed above the 200-day for 96 sessions, since 22 Jun 2026. The 50-day average crossed above the 200-day on 22 Jul 2026, 74 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
July 17, 2026
+16.86%May 6, 2025
−21.08%September 9, 2024
+22.93%